Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Dextroamphetamine Stories

2014-04-08 10:48:49

Genetic variants associated with enjoying the effects of d-amphetamine—the active ingredient in Adderall—are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of amphetamine, is related to...

2014-04-07 12:33:42

Contest for adults who struggle with organization PHILADELPHIA, April 7, 2014 /PRNewswire/ -- Shire today announced the launch of the Organize Your Stuff contest, which is designed for adults who want help organizing their space and reducing clutter. The contest includes the support of expert organizer Monica Friel, president and founder of Chaos to Order, a respected professional organizing service. To enter, adults ages 18 and over can submit a photo to OrganizeYourStuffContest.com. The...

2014-02-25 08:32:17

TORONTO, Feb. 25, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that the Company's President and Chief Executive Officer, David Lickrish, will present at the 34(th) Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Highland's presentation is scheduled for Monday, March 3, 2014 at 11:00am EST. A live webcast of the presentation can be accessed by visiting...

2014-02-06 16:28:08

DUBLIN, February 6, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces top-line results from two pivotal Phase 3 investigational studies evaluating the efficacy and safety of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) versus placebo as an adjunctive treatment for major depressive disorder (MDD) in adults who inadequately responded to antidepressant monotherapy with a SSRI or SNRI. Vyvanse did not meet the primary efficacy endpoint versus placebo for...

2013-11-05 04:23:21

DUBLIN, November 5, 2013 /PRNewswire/ -- Shire Plans to Submit a Supplemental New Drug Application (sNDA) by Q3 2014 Shire plc (LSE: SHP, NASDAQ: SHPG) announces positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) versus placebo in adults with binge eating disorder (BED). In both studies Vyvanse was found to be statistically...

2013-10-15 11:55:31

People with ADHD and substance dependence rarely respond as they should to ADHD medication. A randomized study from Karolinska Institutet now shows that it is possible to obtain the desired efficacy by administering the drug in higher doses. The results of the study are published in the scientific journal Addiction. ADHD is much more common in people who use drugs than in the population at large. ADHD can be treated with methylphenidate, a CNS stimulant used for both children and adults....

2013-07-10 08:27:24

First-to-market generic equivalent of ProCentra® for treatment of ADHD and narcolepsy now available in the U.S. MONMOUTH JUNCTION, N.J., July 10, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that its generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution, the first-to-market generic equivalent of ProCentra®, which is indicated for the treatment of...

2013-06-19 14:32:04

Controversial deals that delay generic versions of drugs coming onto the market can lead to consumers paying significantly more for some treatments, according to new research by an academic from the University of East Anglia. Dr Farasat Bokhari´s study shows that moves to investigate and ban pay-to-delay deals — which typically involve a branded manufacturer holding a drug patent paying a rival generic firm to delay the release of its cheaper version — are justified. The...

2013-05-17 12:23:14

PHILADELPHIA, May 17, 2013 /PRNewswire/ -- Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented...

2013-05-08 08:30:13

CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of a scientific poster titled "Oxycodone DETERx®, an Extended-release, Abuse-deterrent Formulation for the Management of Chronic Pain," at the American Pain Society's 32(nd) Annual Scientific Meeting, held in New Orleans, Louisiana from May 8(th) to May 10(th). This...